0
Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

´Ù¹ß¼º °ñ¼öÁ¾ ȯÀÚÀÇ »îÀÇ Áú

Quality of Life in Patients with Multiple Myeloma

¼ºÀΰ£È£ÇÐȸÁö 2016³â 28±Ç 3È£ p.314 ~ 322
KMID : 0367020160280030314
Á¶°ü¼÷ ( Jo Kwan-Suk ) - °¡Å縯´ëÇб³ ¼­¿ï¼º¸ðº´¿ø °£È£ºÎ

¹ÝÀÚ¿µ ( Ban Ja-Young ) - °¡Å縯´ëÇб³ ¼­¿ï¼º¸ðº´¿ø °£È£ºÎ
À±Áö¿¬ ( Yun Jee-Yeon ) - °¡Å縯´ëÇб³ ¼­¿ï¼º¸ðº´¿ø °£È£ºÎ
±¹½ÂÇý ( Kook Seung-Hye ) - °¡Å縯´ëÇб³ ¼­¿ï¼º¸ðº´¿ø °£È£ºÎ
À±Çö¼± ( Yoon Hyun-Sun ) - °¡Å縯´ëÇб³ ¼­¿ï¼º¸ðº´¿ø °£È£ºÎ
À¯¾ç¼÷ ( Yoo Yang-Sook ) - °¡Å縯´ëÇб³ °£È£´ëÇÐ

Abstract

Purpose: The purpose of this study was to identify the quality of life reported by patients with multiple myeloma and secondly to identify the factors that impact the quality of life (QoL).

Methods: 189 patients with multiple myeloma completed survey questionnaires. Quality of life was evaluated using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core (EORTC QLQ-C) 30 and Multiple Myeloma (MY) 20. The data were analyzed using the t-test, ANOVA, Kruskal-Wallis test, Duncan test and the Mann-Whitney test.

Results: The mean score for each subscale of EORTC QLQ-C30 was 53.35 for global health status, 73.37 for functional scale, and 31.29 for symptom scale. The mean score for each subscale of EORTC QLQ-MY20 was 60.49 for future perspective, 59.78 for body image, 20.25 for disease symptom and 24.99 for side effect of treatment. Quality of life was reported to be significantly lower among females, unemployed, dependence on a sibling for financial support for treatment, a diagnosis of anemia, having treatment, high score on Eastern Coorperative Oncology Group and high grade peripheral neuropathy.

Conclusion: The results of the survey can identify characteristics impacting the QoL of patients with multiple myeloma. Developing appropriate educational strategies and nursing interventions would enhance their QoL.
KeyWords
´Ù¹ß¼º °ñ¼öÁ¾, »îÀÇ Áú, Áõ»ó
Multiple myeloma, Quality of life, Symptom
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
 
µîÀçÀú³Î Á¤º¸
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed